Gilead Issues Statement On Discontinuation Of Magrolimab Study In AML With TP53 Mutations; Says Based On Ad Hoc Analysis And Following Independent Data Monitoring Committe Review, Co. Concluded Magrolimab Unlikely To Demonstrate Survival Benefit
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has announced the discontinuation of its Magrolimab study in Acute Myeloid Leukemia (AML) with TP53 mutations. The decision was based on an ad hoc analysis and an independent data monitoring committee review, which concluded that Magrolimab is unlikely to demonstrate a survival benefit.
September 26, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead's decision to discontinue the Magrolimab study could potentially impact the company's stock negatively in the short term, as it indicates a setback in their product pipeline.
The discontinuation of the Magrolimab study is a significant event for Gilead, as it indicates a potential setback in their product pipeline. This could lead to a negative sentiment among investors, potentially impacting the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100